Precipio (PRPO) Proxy Filing summary

Executive summary

• Urgent request for shareholders and brokers to vote by 11 p.m. ET to ensure quorum for the annual meeting scheduled for June 17, 2025.

• Only 42% of shares have been voted; at least 50% is required to proceed with the meeting.

• Avoiding adjournment could save up to $100,000 in additional costs compared to the current $5,000 meeting expense.

• The company focuses on cancer diagnostics, aiming to reduce misdiagnosis and improve patient outcomes through proprietary technologies.

Voting matters and shareholder proposals

• Shareholders are urged to vote regardless of their stance to meet quorum and avoid costly rescheduling.

Risk oversight and compliance

• Forward-looking statements highlight risks and uncertainties, with actual results potentially differing materially from projections.

• Investors are directed to review risk factors and management's discussion in the latest 10-K and SEC filings.